ADC Therapeutics S.A.ADCTNYSE
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +27.40% | +0.71% | +27.59% | +8.21% | -11.03% |
| Gross Profit Growth | +24.68% | +0.00% | +34.93% | +11.18% | -13.56% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +27.44% | +28.08% | +29.86% | +18.86% | +30.17% |
| Weighted Average Shares Diluted Growth | +27.44% | +28.08% | +29.86% | +18.86% | +30.17% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +13.46% | -19.32% | +36.99% | +14.50% | -4.63% |
| Inventory Growth | -29.29% | +13.66% | +9.06% | +16.93% | +12.26% |
| Asset Growth | -25.23% | -9.25% | -11.50% | -13.51% | -16.99% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +0.83% | -1.11% | +261.86% | -5.53% | -5.85% |
| R&D Expense Growth | +14.28% | -10.65% | +12.41% | +23.85% | -17.53% |
| SG&A Expenses Growth | -10.46% | -17.24% | -102.55% | -9.41% | -8.03% |